Publications

1. Verberkmoes S, Mazza GL, Edmondson AC, Scaglia F, Horikoshi S, Kuschel B, Janssen MCH, Mousa J, Larson A, Shah R, McDonald G, Sarafoglou K, Berry G, Kozicz T, Lam C, Morava E. Goal attainment in PMM2-CDG: A new approach measuring meaningful clinical outcomes. Mol Genet Metab. 2025 Mar 19; 145 (1):109087 [Epub ahead of print]
   View PubMed
2. Mazza GL, Culakova E, Enserro DM, Dignam JJ, Unger JM. Design and analysis considerations for investigating patient subgroups of interest within cancer clinical trials. J Natl Cancer Inst Monogr. 2025 Mar 1; 2025 (68):22-29
   View PubMed
3. Unger JM, Mazza GL, Elsaid MI, Duan F, Dressler EV, Snavely AC, Enserro DM, Pugh SL. When to adjust for multiplicity in cancer clinical trials. J Natl Cancer Inst Monogr. 2025 Mar 1; 2025 (68):3-9
   View PubMed
4. Basch E, Schrag D, Jansen J, Henson S, Ginos B, Stover AM, Carr P, Spears PA, Jonsson M, Deal AM, Bennett AV, Thanarajasingam G, Rogak L, Reeve BB, Snyder C, Bruner D, Cella D, Kottschade LA, Perlmutter J, Geoghegan C, Given B, Mazza GL, Miller R, Strasser JF, Zylla DM, Weiss A, Blinder VS, Wolf AP, Dueck AC. Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial. Nat Med. 2025 Feb 7 Epub 2025 Feb 07
   View PubMed
5. Lee MK, Mitchell SA, Basch E, Mazza GL, Langlais BT, Thanarajasingam G, Ginos BF, Rogak L, Meek EA, Jansen J, Deal AM, Carr P, Blinder VS, Jonsson M, Mody GN, Mendoza TR, Bennett AV, Schrag D, Dueck AC. Identification of meaningful individual-level change thresholds for worsening on the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE(R)). Qual Life Res. 2025 Feb; 34 (2):495-507 Epub 2024 Nov 06
   View PubMed
6. El Sadaney AO, Ferrero A, Rajendran K, Jasper S, Mazza GL, Broski SM, Shanblatt E, Nowak T, Fletcher JG, McCollough CH, Baffour FI. Opportunistic Bone Mineral Density Measurement Using Photon-Counting Detector CT Spectral Localizer Images: A Prospective Study. AJR Am J Roentgenol. 2025 Jan; 224 (1):e2431909 Epub 2024 Oct 30
   View PubMed
7. Patel BK, Carnahan MB, Northfelt D, Anderson K, Mazza GL, Pizzitola VJ, Giurescu ME, Lorans R, Eversman WG, Sharpe RE Jr, Harper LK, Apsey H, Cronin P, Kling J, Ernst B, Palmieri J, Fraker J, Mina L, Batalini F, Pockaj B. Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round. J Clin Oncol. 2024 Nov 10; 42 (32):3826-3836 Epub 2024 July 26
   View PubMed
8. Mead-Harvey C, Basch E, Rogak LJ, Langlais BT, Thanarajasingam G, Ginos BF, Lee MK, Yee C, Mitchell SA, Minasian LM, Mendoza TR, Bennett AV, Schrag D, Dueck AC, Mazza GL. Statistical properties of items and summary scores from the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE((R))) in a diverse cancer sample. Clin Trials. 2024 Oct 23; 17407745241286065 [Epub ahead of print]
   View PubMed
9. Langlais B, Dueck AC, Kosiorek HE, Mead-Harvey C, Meek E, Rogak L, Mascarenhas J, Mesa R, Gowin K, Palmer J, Scherber R, Marcellino B, Hoffman R, Mazza GL. Impact of gender representativeness in online symptom survey and clinical trial participation among patients with myeloproliferative neoplasms. Leuk Lymphoma. 2024 Oct; 65 (10):1465-1473 Epub 2024 June 02
   View PubMed
10. Lam C, Scaglia F, Berry GT, Larson A, Sarafoglou K, Andersson HC, Sklirou E, Tan QKG, Starosta RT, Sadek M, Wolfe L, Horikoshi S, Ali M, Barone R, Campbell T, Chang IJ, Coles K, Cook E, Eklund EA, Engelhardt NM, Freeman M, Friedman J, Fu DYT, Botzo G, Rawls B, Hernandez C, Johnsen C, Keller K, Kramer S, Kuschel B, Leshinski A, Martinez-Duncker I, Mazza GL, Mercimek-Andrews S, Miller BS, Muthusamy K, Neira J, Patterson MC, Pogorelc N, Powers LN, Ramey E, Reinhart M, Squire A, Thies J, Vockley J, Vreugdenhil H, Witters P, Youbi M, Zeighami A, Zemet R, Edmondson AC, Morava E. Frontiers in congenital disorders of glycosylation consortium, a cross-sectional study report at year 5 of 280 individuals in the natural history cohort. Mol Genet Metab. 2024 Aug; 142(4):108509. Epub 2024 Jun 06.
    View PubMed
11. Mazza GL, Dueck AC, Ginos B, Jansen J, Deal AM, Carr P, Blinder VS, Thanarajasingam G, Jonsson M, Lee MK, Rogak LJ, Mody GN, Schrag D, Basch E. Optimization of alert notifications in electronic patient-reported outcome (ePRO) remote symptom monitoring systems (AFT-39). Qual Life Res. 2024 Jul; 33 (7):1985-1995 Epub 2024 May 21
    View PubMed
12. Austin JD, James E, Perez RL, Mazza GL, Kling JM, Fraker J, Mina L, Banerjee I, Sharpe R, Patel BK. Factors influencing U.S. women's interest and preferences for breast cancer risk communication: a cross-sectional study from a large tertiary care breast imaging center. BMC Womens Health. 2024 Jun 21; 24 (1):359 Epub 2024 June 21
    View PubMed
13. Patel BK, Gurudu R, Mazza G, Sharpe RE Jr, Mina L, Fraker J, Kling JM, Anderson K, Hughes D, Pockaj B. Patient-Reported Testing Burden of Screening Contrast-Enhanced Mammography. J Am Coll Radiol. 2024 May; 21 (5):789-794 Epub 2023 Nov 11
    View PubMed
14. Smith KL, Mead-Harvey C, Mazza GL, Shinn EH, Frank ES, Melisko ME, Eaton C, Liu Y, Salamone JM, Pollastro T, Spears PA, Caston NE, Wolff AC, Rocque GB. TBCRC 057: Survey about willingness to participate in cancer clinical trials during the pandemic. Cancer Med. 2024 Mar; 13 (5):e7090
    View PubMed
15. Blinder VS, Deal AM, Ginos B, Jansen J, Dueck AC, Mazza GL, Henson S, Carr P, Rogak LJ, Weiss A, Rapperport A, Jonsson M, Spears PA, Cella D, Gany F, Schrag D, Basch E. Financial Toxicity Monitoring in a Randomized Controlled Trial of Patient-Reported Outcomes During Cancer Treatment (Alliance AFT-39). J Clin Oncol. 2023 Oct 10; 41 (29):4652-4663 Epub 2023 Aug 25
    View PubMed
16. Hu LS, D'Angelo F, Weiskittel TM, Caruso FP, Fortin Ensign SP, Blomquist MR, Flick MJ, Wang L, Sereduk CP, Meng-Lin K, De Leon G, Nespodzany A, Urcuyo JC, Gonzales AC, Curtin L, Lewis EM, Singleton KW, Dondlinger T, Anil A, Semmineh NB, Noviello T, Patel RA, Wang P, Wang J, Eschbacher JM, Hawkins-Daarud A, Jackson PR, Grunfeld IS, Elrod C, Mazza GL, McGee SC, Paulson L, Clark-Swanson K, Lassiter-Morris Y, Smith KA, Nakaji P, Bendok BR, Zimmerman RS, Krishna C, Patra DP, Patel NP, Lyons M, Neal M, Donev K, Mrugala MM, Porter AB, Beeman SC, Jensen TR, Schmainda KM, Zhou Y, Baxter LC, Plaisier CL, Li J, Li H, Lasorella A, Quarles CC, Swanson KR, Ceccarelli M, Iavarone A, Tran NL. Integrated molecular and multiparametric MRI mapping of high-grade glioma identifies regional biologic signatures. Nat Commun. 2023 Sep 28; 14 (1):6066 Epub 2023 Sept 28
    View PubMed
17. Basch E, Dueck AC, Mitchell SA, Mamon H, Weiser M, Saltz L, Gollub M, Rogak L, Ginos B, Mazza GL, Colgrove B, Chang G, Minasian L, Denicoff A, Thanarajasingam G, Musher B, George T, Venook A, Farma J, O'Reilly E, Meyerhardt JA, Shi Q, Schrag D. Patient-Reported Outcomes During and After Treatment for Locally Advanced Rectal Cancer in the PROSPECT Trial (Alliance N1048). J Clin Oncol. 2023 Jul 20; 41 (21):3724-3734 Epub 2023 June 04
    View PubMed
18. Lee MK, Basch E, Mitchell SA, Minasian LM, Langlais BT, Thanarajasingam G, Ginos BF, Rogak LJ, Mendoza TR, Bennett AV, Schrag D, Mazza GL, Dueck AC. Reliability and validity of PRO-CTCAE(R) daily reporting with a 24-hour recall period. Qual Life Res. 2023 Jul; 32 (7):2047-2058 Epub 2023 Mar 10
    View PubMed
19. De Graef D, Ligezka AN, Rezents J, Mazza GL, Preston G, Schwartz K, Krzysciak W, Lam C, Edmondson AC, Johnsen C, Kozicz T, Morava E. Coagulation abnormalities in a prospective cohort of 50 patients with PMM2-congenital disorder of glycosylation. Mol Genet Metab. 2023 Jun; 139 (2):107606 Epub 2023 May 09
    View PubMed
20. Viggiano T, Scott R, Sharpe R, Kasper C, Mazza G, Pizzitola V, Giurescu M, Lorans R, Eversman W, Patel BK. Contrast Enhanced Mammography in Routine Clinical Practice: Frequency and Malignancy Rates of Enhancing Otherwise Occult Findings. Clin Breast Cancer. 2022 Oct; 22 (7):e736-e744 Epub 2022 July 23
    View PubMed
21. Sonbol MB, Mazza GL, Mi L, Oliver T, Starr J, Gudmundsdottir H, Cleary SP, Hobday T, Halfdanarson TR. Survival and Incidence Patterns of Pancreatic Neuroendocrine Tumors Over the Last 2 Decades: A SEER Database Analysis. Oncologist. 2022 Jul 5; 27 (7):573-578
    View PubMed
22. Patel BK, Pepin K, Brandt KR, Mazza GL, Pockaj BA, Chen J, Zhou Y, Northfelt DW, Anderson K, Kling JM, Vachon CM, Swanson KR, Nikkhah M, Ehman R. Association of breast cancer risk, density, and stiffness: global tissue stiffness on breast MR elastography (MRE). Breast Cancer Res Treat. 2022 Jul; 194 (1):79-89 Epub 2022 Apr 30
    View PubMed
23. Thanarajasingam G, Basch E, Mead-Harvey C, Bennett AV, Mazza GL, Schwab G, Roydhouse J, Rogak LJ, Dueck AC. An Exploratory Analysis of the "Was It Worth It?" Questionnaire as a Novel Metric to Capture Patient Perceptions of Cancer Treatment. Value Health. 2022 Jul; 25 (7):1081-1086 Epub 2022 Jan 03
    View PubMed
24. Basch E, Schrag D, Henson S, Jansen J, Ginos B, Stover AM, Carr P, Spears PA, Jonsson M, Deal AM, Bennett AV, Thanarajasingam G, Rogak LJ, Reeve BB, Snyder C, Bruner D, Cella D, Kottschade LA, Perlmutter J, Geoghegan C, Samuel-Ryals CA, Given B, Mazza GL, Miller R, Strasser JF, Zylla DM, Weiss A, Blinder VS, Dueck AC. Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial. JAMA. 2022 Jun 28; 327 (24):2413-2422
    View PubMed
25. Scherer EA, Kim SJ, Metcalf SA, Sweeney MA, Wu J, Xie H, Mazza GL, Valente MJ, MacKinnon DP, Marsch LA. Momentary Self-regulation: Scale Development and Preliminary Validation. JMIR Ment Health. 2022 May 10; 9 (5):e35273
    View PubMed
26. Kroenke K, Miksch TA, Spaulding AC, Mazza GL, DeStephano CC, Niazi SK, Illies AJC, Bydon M, Novotny PJ, Goyal A, Lee MK. Choosing and Using Patient-Reported Outcome Measures in Clinical Practice. Arch Phys Med Rehabil. 2022 May; 103 (5S):S108-S117 Epub 2021 Mar 10
    View PubMed
27. Mazza GL, Petersen MM, Ginos B, Langlais BT, Heon N, Gounder MM, Mahoney MR, Zoroufy AJ, Schwartz GK, Rogak LJ, Thanarajasingam G, Basch E, Dueck AC. Missing data strategies for the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Alliance A091105 and COMET-2. Qual Life Res. 2022 Apr; 31 (4):1069-1080 Epub 2021 Aug 21
    View PubMed
28. Langlais B, Mazza GL, Thanarajasingam G, Rogak LJ, Ginos B, Heon N, Scher HI, Schwab G, Ganz PA, Basch E, Dueck AC. Evaluating Treatment Tolerability Using the Toxicity Index With Patient-Reported Outcomes Data. J Pain Symptom Manage. 2022 Feb; 63 (2):311-320 Epub 2021 Aug 08
    View PubMed
29. Mazza GL, Mead-Harvey C, Mascarenhas J, Yacoub A, Kosiorek HE, Hoffman R, Dueck AC, Mesa RA, Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 trial teams. Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials. Lancet Haematol. 2022 Jan; 9 (1):e38-e48
    View PubMed
30. Langlais BT, Mazza GL, Kosiorek HE, Palmer J, Mesa R, Dueck AC. Validation of a Modified Version of the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score. J Hematol. 2021 Oct; 10 (5):207-211 Epub 2021 Oct 31
    View PubMed
31. Christensen SF, Scherber RM, Mazza GL, Dueck AC, Brochmann N, Andersen CL, Hasselbalch HC, Mesa RA, Geyer HL. Tobacco use in the Myeloproliferative neoplasms: symptom burden, patient opinions, and care. BMC Cancer. 2021 Jun 10; 21 (1):691 Epub 2021 June 10
    View PubMed
32. Mazza GL, Smyth HL, Bissett PG, Canning JR, Eisenberg IW, Enkavi AZ, Gonzalez O, Kim SJ, Metcalf SA, Muniz F, Pelham WE 3rd, Scherer EA, Valente MJ, Xie H, Poldrack RA, Marsch LA, MacKinnon DP. Correlation Database of 60 Cross-Disciplinary Surveys and Cognitive Tasks Assessing Self-Regulation. J Pers Assess. 2021 Mar-Apr; 103 (2):238-245 Epub 2020 Mar 09
    View PubMed
33. Hu LS, Wang L, Hawkins-Daarud A, Eschbacher JM, Singleton KW, Jackson PR, Clark-Swanson K, Sereduk CP, Peng S, Wang P, Wang J, Baxter LC, Smith KA, Mazza GL, Stokes AM, Bendok BR, Zimmerman RS, Krishna C, Porter AB, Mrugala MM, Hoxworth JM, Wu T, Tran NL, Swanson KR, Li J. Uncertainty quantification in the radiogenomics modeling of EGFR amplification in glioblastoma. Sci Rep. 2021 Feb 16; 11 (1):3932
    View PubMed
34. Novotny PJ, Schroeder D, Sloan JA, Mazza GL, Williams D, Bradley D, Haller IV, Bradley SM, Croghan I. Do Missing Values Influence Outcomes in a Cross-sectional Mail Survey? Mayo Clin Proc Innov Qual Outcomes. 2021 Feb; 5 (1):84-93 Epub 2021 Jan 19
    View PubMed
35. DeWees TA, Mazza GL, Golafshar MA, Dueck AC. Investigation Into the Effects of Using Normal Distribution Theory Methodology for Likert Scale Patient-Reported Outcome Data From Varying Underlying Distributions Including Floor/Ceiling Effects. Value Health. 2020 May; 23 (5):625-631 Epub 2020 Mar 06
    View PubMed
36. Pina AA, Gonzales NA, Mazza GL, Gunn HJ, Holly LE, Stoll RD, Parker J, Chiapa A, Wynne H, Tein JY. Streamlined Prevention and Early Intervention for Pediatric Anxiety Disorders: A Randomized Controlled Trial. Prev Sci. 2020 May; 21 (4):487-497
    View PubMed
37. Valente MJ, MacKinnon DP, Mazza GL. A Viable Alternative When Propensity Scores Fail: Evaluation of Inverse Propensity Weighting and Sequential G-Estimation in a Two-Wave Mediation Model. Multivariate Behav Res. 2020 Mar-Apr; 55 (2):165-187 Epub 2019 June 20
    View PubMed
38. Hoxworth JM, Eschbacher JM, Gonzales AC, Singleton KW, Leon GD, Smith KA, Stokes AM, Zhou Y, Mazza GL, Porter AB, Mrugala MM, Zimmerman RS, Bendok BR, Patra DP, Krishna C, Boxerman JL, Baxter LC, Swanson KR, Quarles CC, Schmainda KM, Hu LS. Performance of Standardized Relative CBV for Quantifying Regional Histologic Tumor Burden in Recurrent High-Grade Glioma: Comparison against Normalized Relative CBV Using Image-Localized Stereotactic Biopsies. AJNR Am J Neuroradiol. 2020 Mar; 41 (3):408-415 Epub 2020 Mar 12
    View PubMed
39. Dueck AC, Scher HI, Bennett AV, Mazza GL, Thanarajasingam G, Schwab G, Weitzman AL, Rogak LJ, Basch E. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial. JAMA Oncol. 2020 Feb 1; 6 (2):e193332 Epub 2020 Feb 13
    View PubMed
40. Curtin L, Whitmire P, Rickertsen CR, Mazza GL, Canoll P, Johnston SK, Mrugala MM, Swanson KR, Hu LS. Assessment of Prognostic Value of Cystic Features in Glioblastoma Relative to Sex and Treatment With Standard-of-Care. Front Oncol. 2020; 10:580750 Epub 2020 Nov 16
    View PubMed
41. Enkavi AZ, Eisenberg IW, Bissett PG, Mazza GL, MacKinnon DP, Marsch LA, Poldrack RA. Reply to Friedman and Banich: Right measures for the research question. Proc Natl Acad Sci U S A 2019 Dec 3; 116 (49):24398-24399 Epub 2019 Nov 12
    View PubMed
42. Mazza GL, Kunze KL, Langlais BT, Kosiorek HE, DeWees TA, Geyer HL, Scherber RM, Mesa RA, Dueck AC. Item nonresponse on the Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF): a comparison of missing data strategies. Leuk Lymphoma. 2019 Jul; 60(7):1789-1795. Epub 2019 Jan 17.
    View PubMed
43. Enkavi AZ, Eisenberg IW, Bissett PG, Mazza GL, MacKinnon DP, Marsch LA, Poldrack RA. Large-scale analysis of test-retest reliabilities of self-regulation measures. Proc Natl Acad Sci U S A. 2019 Mar 19; 116 (12):5472-5477 Epub 2019 Mar 06
    View PubMed
44. Sandler I, Wolchik S, Mazza G, Gunn H, Tein J-Y, Berkel C, Jones S, Porter M. Randomized effectiveness trial of the New Beginnings Program for divorced families with children and adolescents. J Clin Child Adolesc Psychol. 2019.
    
45. Sandler I, Gunn H, Mazza G, Tein JY, Wolchik S, Kim H, Ayers T, Porter M. Three perspectives on mental health problems of young adults and their parents at a 15-year follow-up of the family bereavement program. J Consult Clin Psychol. 2018 Oct; 86 (10):845-855
    View PubMed
46. Mazza GL, Tein J-Y, Gunn HJ, Kim H, Stuart EA, Sandler IN, Wolchik S. Multigroup Propensity Score Approach to Evaluating an Effectiveness Trial of the New Beginnings Program. Evaluation & the Health Professions. 2018; 41(2):290-320. Epub 2018 Apr 10.
    
47. Sandler I, Gunn H, Mazza G, Tein JY, Wolchik S, Berkel C, Jones S, Porter M. Effects of a Program to Promote High Quality Parenting by Divorced and Separated Fathers. Prev Sci. 2018 May; 19 (4):538-548
    View PubMed
48. Eisenberg IW, Bissett PG, Canning JR, Dallery J, Enkavi AZ, Whitfield-Gabrieli S, Gonzalez O, Green AI, Greene MA, Kiernan M, Kim SJ, Li J, Lowe MR, Mazza GL, Metcalf SA, Onken L, Parikh SS, Peters E, Prochaska JJ, Scherer EA, Stoeckel LE, Valente MJ, Wu J, Xie H, MacKinnon DP, Marsch LA, Poldrack RA. Applying novel technologies and methods to inform the ontology of self-regulation. Behav Res Ther. 2018 Feb; 101:46-57 Epub 2017 Oct 05
    View PubMed
49. Knight GP, Mazza GL, Carlo G. Trajectories of familism values and the prosocial tendencies of Mexican American adolescents. Dev Psychol. 2018 Feb; 54 (2):378-384 Epub 2017 Oct 30
    View PubMed
50. Modecki KL, Mazza GL. Are we making the most of ecological momentary assessment data? A comment on Richardson, Fuller-Tyszkiewicz, O'Donnell, Ling, & Staiger, 2017. Health Psychol Rev. 2017 Sep; 11 (3):295-297 Epub 2017 July 11
    View PubMed
51. Mauricio AM, Mazza GL, Berkel C, Tein JY, Sandler IN, Wolchik SA, Winslow E. Attendance Trajectory Classes Among Divorced and Separated Mothers and Fathers in the New Beginnings Program. Prev Sci. 2017 Mar 29 [Epub ahead of print]
    View PubMed
52. Grimm KJ, Mazza GL, Davoudzadeh P. Model Selection in Finite Mixture Models: A k-Fold Cross-Validation Approach. Structural Equation Modeling. 2016; 24(2):246-256.
    
53. Grimm KJ, Mazza GL, Mazzocco MMM. Advances in Methods for Assessing Longitudinal Change. Educational Psychologist. 2016; 51(3-4):342-353.
    
54. Mazza GL, Enders CK, Ruehlman LS. Addressing Item-Level Missing Data: A Comparison of Proration and Full Information Maximum Likelihood Estimation. Multivariate Behav Res. 2015; 50 (5):504-19
    View PubMed